- Meeting abstract
- Open access
- Published:
The use of amisulpride in schizophrenic patients with resistant symptomatology
Annals of General Psychiatry volume 9, Article number: S135 (2010)
Background
The purpose of this study was to evaluate the use of the pharmaceutical drug Amisulpride (Solian) in schizophrenic patients with resistant semiology
Materials and methods
The material of this study was 21 patients (17 men and 4 women) who were diagnosed with schizophrenic disorder paranoid type based on DSM-IV, and were recorded with durable symptomatology (delusions, paranoid ideas etc.) even though the continuous issuing of Amisulpride in normal doses (800-1200 mg/daily). In these patients was given Amisulpride in larger doses than the proposed (1600-2000 mg/daily). The evaluation was done with the PANSS scale
Results
After a 30 day time interval and while the continuous issuing of Amisulpride in larger doses was observed considerably reprocess of the resistant symptoms, fact that recorded at the grade alleviation at PANSS scale
Conclusions
Is concluding that the continuous issuing of Amisulpride in larger doses than the normal ones help considerably in obliteration of the durable symptoms of schizophrenia.
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Kalfas, D., Markou, S., Gkletsos, A. et al. The use of amisulpride in schizophrenic patients with resistant symptomatology. Ann Gen Psychiatry 9 (Suppl 1), S135 (2010). https://doi.org/10.1186/1744-859X-9-S1-S135
Published:
DOI: https://doi.org/10.1186/1744-859X-9-S1-S135